Global Iron Deficiency Anemia Therapy Market Size, Share, and COVID-19 Impact Analysis, By Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusions, and Others), By Age Group (Adults, Pediatric, and Geriatric), By End-user (Clinics, Hospitals, and Home Healthcare), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Iron Deficiency Anemia Therapy Market Insights Forecasts to 2035

• The Global Iron Deficiency Anemia Therapy Market Size Was Estimated at USD 5.08 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.6% from 2025 to 2035
• The Worldwide Iron Deficiency Anemia Therapy Market Size is Expected to Reach USD 10.26 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, the global iron deficiency anemia therapy market size was worth around USD 5.08 billion in 2024 and is predicted to grow to around USD 10.26 billion by 2035 with a compound annual growth rate (CAGR) of 6.6% from 2025 to 2035. The growth of the iron deficiency anemia therapy market is driven by increasing anemia prevalence, advancements in iron formulations, rising awareness of nutritional health, government initiatives to reduce anemia, and growing adoption of effective intravenous iron therapies across healthcare systems worldwide.

Market Overview

The Global Iron Deficiency Anemia (IDA) Therapy Market Size refers to therapies for restoring normal levels of iron and improving the production of red blood cells in patients suffering from anemia due to either low intake or poor absorption of iron. IDA is one of the most prevalent nutritional disorders globally, affecting diverse populations, especially among women of reproductive age, children, and people with chronic diseases. Therapies range from oral iron supplements and intravenous iron formulations to novel fixed-dose combination treatments aiming to enhance absorption and minimize side effects. Strong growth in the global prevalence of anemia, increasing awareness of nutritional deficiencies, and expanding healthcare infrastructure in emerging markets are the primary forces driving market growth. Advanced IV iron formulations have gained rapid demand due to their high efficacy and quicker response for severe cases.

Nanoparticle-based iron therapies, in conjunction with controlled-release formulations of drugs, will expand the treatment landscape with improved safety and adherence in patients. Opportunities abound in untapped markets across Asia Pacific, Latin America, and Africa, where government initiatives to combat malnutrition and anemia are accelerating healthcare investments. Strategic collaborations and novel research, cost-effective therapies further expand market potential. Key companies in the sector include Vifor Pharma, Daiichi Sankyo Company, AMAG Pharmaceuticals, Pfizer Inc., Sanofi, Akebia Therapeutics, and Pharmacosmos AS, all focusing on product innovation, geographic expansion, and a patient-centric treatment approach to strengthen their global presence. On August 06, 2024, the Government of India expanded the Anemia Mukt Bharat strategy using the 6×6×6 model targeting six groups: children (6-59 months, 5-9 years), adolescents, women of reproductive age, pregnant and lactating women through six interventions such as iron-folic acid supplementation, deworming, fortified foods, awareness, testing, and six institutional mechanisms for coordination, capacity building, logistics, and real-time monitoring through the AMB dashboard.

Report Coverage

This research report categorizes the iron deficiency anemia therapy market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the iron deficiency anemia therapy market. Recent market developments and competitive strategies, such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the iron deficiency anemia therapy market. 

Driving Factors

The Iron Deficiency Anemia Therapy Market Size is propelled by the increasing prevalence of anemia, especially in women, children, and the geriatric population. Increasing awareness of nutritional disorders, combined with rising healthcare expenditure and the availability of better iron supplements and formulations, has led to the growth of the market. Besides these factors, expanded access to diagnostic facilities, government efforts to control malnutrition, and the increasing prevalence of diseases associated with iron deficiency, such as chronic kidney disease and gastrointestinal disorders, further drive demand. Moreover, ongoing research into new ways of drug delivery and the introduction of safer, faster-acting iron replacement products add to the market growth.

Restraining Factors

There are some limiting factors for the iron deficiency anemia therapy market, which include side effects that may be associated with iron supplements, such as gastrointestinal discomfort and allergic reactions. The high cost of treatments, limited access to advanced therapies in developing regions, and poor patient compliance act as a barrier to growth. Besides, misdiagnosis, underreporting of anemia cases, and strict regulatory requirements further restrain market growth.

Market Segmentation

The iron deficiency anemia therapy market share is classified into type, age group, and end-user.  

• The oral iron therapy segment dominated the market in 2024, approximately 42% and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the iron deficiency anemia therapy market is divided into oral iron therapy, parenteral iron therapy, red blood cell transfusions, and others. Among these, the oral iron therapy segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The oral iron therapy segment dominated the global iron deficiency anemia market, due to oral iron preparations being cheaper, easier to administer, and more accessible, hence, they are the first choice for mild to moderate anemia. Growing awareness about iron supplementation, increasing cases of anemia among women and children, and supportive government nutrition policies contribute significantly toward higher demand for oral iron therapies.

• The adults segment accounted for the largest share in 2024, approximately 60% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the age group, the iron deficiency anemia therapy market size is divided into adults, pediatric, and geriatric. Among these, the adults segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. There is a high prevalence of anemia among women of childbearing age, pregnant women, and patients suffering from chronic diseases such as CKD, gastrointestinal disorders, and cancer, thus, the adult segment dominated the market. High iron needs, blood loss, and widespread use of oral and IV iron therapies across hospitals, clinics, and home care propelled the dominance further.

• The hospitals segment accounted for the highest market revenue in 2024, approximately 38% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end-user, the iron deficiency anemia therapy market size is divided into clinics, hospitals, and home healthcare. Among these, the hospitals segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The hospitals segment dominated the market due to a high demand for hospital-based treatment of complicated and chronic anemia. The services offered in hospitals include IV iron therapy, blood transfusions, and care for conditions such as CKD, cancer, and IBD. Advanced diagnostics, multi-disciplinary care teams, and comprehensive treatment plans further increase patient volume and solidify hospitals as the preferred treatment setting.

Regional Segment Analysis of the Iron Deficiency Anemia Therapy Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the iron deficiency anemia therapy market over the predicted timeframe.

North America is anticipated to hold the largest share of the iron deficiency anemia therapy market size over the predicted timeframe. North America is expected to lead the iron deficiency anemia therapy market during the forecast period, with an approximate 38% market share, mainly due to greater awareness of nutritional deficiencies and well-established healthcare infrastructure. Other factors driving growth include widespread acceptance of advanced therapies, such as oral and intravenous iron supplements. The United States represents the major share in the regional market, driven by favorable reimbursement policies, diagnostics, and a strong network of multispecialty and general hospitals. Also, strong governmental programs that involve the screening for anemia, rising prevalence of chronic diseases such as chronic kidney disease and cancer, and increasing demand for effective treatment options are some key factors driving the market.

Asia Pacific is expected to grow at a rapid CAGR in the iron deficiency anemia therapy market size during the forecast period. The Asia Pacific, during the forecast period, with an approximately 25% market share, is rapidly growing in the iron deficiency anemia therapy market due to its large population, high prevalence of anemia, and increasing access to healthcare facilities. India leads in the regional market due to nationwide programs such as Anemia Mukt Bharat, focusing on supplementation, food fortification, and awareness for children, adolescents, and women. Other major contributors that will drive the robust growth of this region's market include growing urbanization, better hospital infrastructure, expanding government initiatives, and rising awareness related to iron deficiency therapies in China and Southeast Asia.

On 19 September 2024, India will run the world’s largest universal adolescent anemia control programme, targeting 116 million adolescents. It aims to prevent anemia’s harmful effects, break the intergenerational malnutrition cycle, and promote good nutrition with adequate iron. India’s 15-year nationwide effort provides key insights and lessons for other countries addressing adolescent anemia.

Europe’s iron deficiency anemia therapy market is growing steadily, driven by increasing prevalence of anemia, aging populations, and rising chronic diseases such as cancer and chronic kidney disease. Germany leads the regional market due to advanced healthcare infrastructure, widespread anemia screening programs, and strong adoption of oral and intravenous iron therapies. Supportive government policies, reimbursement frameworks, and growing awareness among healthcare providers and patients further contribute to the consistent growth of the European market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the iron deficiency anemia therapy market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Akebia Therapeutics Inc.
• Bayer AG
• AbbVie Inc.
• Pharmacosmos AS
• Daiichi Sankyo
• Johnson and Johnson
• Pfizer Inc.
• AMAG Pharmaceuticals Inc.
• Apotex Inc.
• Sanofi SA
• Rockwell Medical, Inc.
• Vifor Pharma Management Ltd.
• AdvaCare Pharma
• Fresenius SE & Co. KGaA
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In September 2025, Bayer’s Consumer Health launched Supradyn Mom’s and Supradyn Naturals Calcium+ in India to address nutritional deficiencies during preconception, pregnancy, and lactation. With nearly 60% of Indian women anaemic and over 70% calcium-deficient, iron deficiency anemia significantly impacts maternal-child health and contributes up to 1.18% of India’s GDP loss.

• In May 2025, SteinCares and Pharmacosmos launched Monofer, an intravenous iron therapy, in six Latin American markets: Ecuador, Dominican Republic, Guatemala, Chile, Panama, and Costa Rica. The partnership highlights SteinCares’ commitment to delivering high-quality, cost-effective treatments and bridging global specialty care innovations with Latin America’s unmet healthcare needs.

• In January 2024, the UK Competition and Markets Authority (CMA) launched an investigation into Vifor Pharma for suspected anti-competitive conduct in supplying IV iron treatments. The probe examines whether Vifor, maker of Ferinject, misled healthcare professionals about Monofer, a rival IV iron therapy by Pharmacosmos, to restrict competition.

• In June 2023, Daiichi Sankyo and American Regent announced FDA approval of INJECTAFER (ferric carboxymaltose) for treating iron deficiency in adult heart failure patients (NYHA class II/III) to improve exercise capacity, marking a significant advancement in managing iron deficiency among cardiovascular patients in the U.S.

• In March 2023, Pharmacosmos announced that MonoVer (ferric derisomaltose) received national reimbursement in Japan and is launching in the country, the world’s third-largest pharma market. MonoVer is an intravenous iron therapy for iron deficiency anemia (IDA), used when oral iron is ineffective, unsuitable, or rapid iron delivery is required.

• In February 2022, the FDA approved Sanofi’s Enjaymo to reduce red blood cell transfusions in adults with cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia. In CAD, cold agglutinins trigger the immune system to attack and destroy healthy red blood cells, leading to hemolysis.

Market Segment                                                              

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the iron deficiency anemia therapy market based on the below-mentioned segments: 

Global Iron Deficiency Anemia Therapy Market, By Type

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusions
• Others

Global Iron Deficiency Anemia Therapy Market, By Age Group

• Adults
• Pediatric
• Geriatric

Global Iron Deficiency Anemia Therapy Market, By End-user

• Clinics
• Hospitals
• Home Healthcare

Global Iron Deficiency Anemia Therapy Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa